日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials

大麻二酚(Epidyolex®)用于治疗结节性硬化症、III型粘多糖贮积症和脆性X综合征患者的严重行为表现:一系列随机、安慰剂对照的N-of-1试验方案

Müller, A R; den Hollander, B; van de Ven, P M; Roes, K C B; Geertjens, L; Bruining, H; van Karnebeek, C D M; Jansen, F E; de Wit, M C Y; Ten Hoopen, L W; Rietman, A B; Dierckx, B; Wijburg, F A; Boot, E; Brands, M M G; van Eeghen, A M

Introduction of Ultra-High-Field MR Imaging in Infants: Preparations and Feasibility

超高场磁共振成像在婴幼儿中的应用:准备工作和可行性

Annink, K V; van der Aa, N E; Dudink, J; Alderliesten, T; Groenendaal, F; Lequin, M; Jansen, F E; Rhebergen, K S; Luijten, P; Hendrikse, J; Hoogduin, H J M; Huijing, E R; Versteeg, E; Visser, F; Raaijmakers, A J E; Wiegers, E C; Klomp, D W J; Wijnen, J P; Benders, M J N L

Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors

难治性青少年肌阵挛性癫痫:患病率和危险因素的荟萃分析

Stevelink, R; Koeleman, B P C; Sander, J W; Jansen, F E; Braun, K P J

Promoter-Specific Hypomethylation Correlates with IL-1β Overexpression in Tuberous Sclerosis Complex (TSC).

启动子特异性低甲基化与结节性硬化症 (TSC) 中的 IL-1β 过表达相关

Fuso A, Iyer A M, van Scheppingen J, Maccarrone M, Scholl T, Hainfellner J A, Feucht M, Jansen F E, Spliet W G, Krsek P, Zamecnik J, Mühlebner A, Aronica E

Tuberous sclerosis complex and its founders

结节性硬化症及其创始人

Jansen, F E; van Nieuwenhuizen, O; van Huffelen, A C